Where Will Pfizer Be in 10 Years?
(NYSE: PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That product, Comirnaty, and the treatment Paxlovid, released later, helped Pfizer's revenue reach a record level of $100 billion in 2022; the two products made up more than half of that.
Now, though, with coronavirus product demand falling and losses of exclusivity ahead for some of Pfizer's other drugs, the company's revenue is on the decline. And Pfizer's shares, after climbing to a peak back in 2021, have now dropped nearly 50% from that level.
But this pharmaceutical giant hasn't turned the final page in its growth story; instead, it's taken steps to renew its portfolio of products and boost revenue. Where will Pfizer be in 10 years? Let's find out.
Source Fool.com
Pfizer Inc. Aktie
Die Pfizer Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Das Kursziel von 41 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 25.77 €.
